Jasper Therapeutics (NASDAQ:JSPRW – Get Free Report) is expected to announce its results before the market opens on Tuesday, March 10th. Analysts expect the company to announce earnings of ($0.6689) per share for the quarter.
Jasper Therapeutics Stock Up 2.0%
Shares of NASDAQ:JSPRW opened at $0.02 on Monday. The company has a 50 day moving average price of $0.04 and a two-hundred day moving average price of $0.08. Jasper Therapeutics has a 52 week low of $0.02 and a 52 week high of $0.18.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.
The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.
Read More
- Five stocks we like better than Jasper Therapeutics
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
